Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Capital Expenditures: 2020-2025

Historic Capital Expenditures for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Sep 2025 value amounting to $2.9 million.

  • Maravai Lifesciences Holdings' Capital Expenditures fell 65.94% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.9 million, marking a year-over-year decrease of 58.42%. This contributed to the annual value of $29.7 million for FY2024, which is 54.76% down from last year.
  • Maravai Lifesciences Holdings' Capital Expenditures amounted to $2.9 million in Q3 2025, which was up 1.81% from $2.9 million recorded in Q2 2025.
  • Over the past 5 years, Maravai Lifesciences Holdings' Capital Expenditures peaked at $25.1 million during Q2 2023, and registered a low of $1.3 million during Q3 2021.
  • Its 3-year average for Capital Expenditures is $9.7 million, with a median of $7.9 million in 2023.
  • In the last 5 years, Maravai Lifesciences Holdings' Capital Expenditures crashed by 86.83% in 2021 and then soared by 1,408.67% in 2023.
  • Over the past 5 years, Maravai Lifesciences Holdings' Capital Expenditures (Quarterly) stood at $5.7 million in 2021, then climbed by 9.87% to $6.2 million in 2022, then skyrocketed by 170.34% to $16.8 million in 2023, then slumped by 65.18% to $5.8 million in 2024, then crashed by 65.94% to $2.9 million in 2025.
  • Its Capital Expenditures stands at $2.9 million for Q3 2025, versus $2.9 million for Q2 2025 and $5.2 million for Q1 2025.